Actively Recruiting
High Dose Re-Irradiation Utilizing Advanced Deformable Image Registration (DIR) and Individualized Organ At Risk (OAR) Dose Calculations With Organ Specific Toxicity Analysis
Led by Medical College of Wisconsin · Updated on 2025-06-29
120
Participants Needed
1
Research Sites
315 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This trial applies a uniform approach to re-irradiation for planning and diagnostic image fusion, dose summation, dose calculations, and follow up for tumor control and detailed toxicity analysis of serial Organs At Risk (OARs). Serial organs include named arteries and nerves, spinal cord, and gastrointestinal tract.
CONDITIONS
Official Title
High Dose Re-Irradiation Utilizing Advanced Deformable Image Registration (DIR) and Individualized Organ At Risk (OAR) Dose Calculations With Organ Specific Toxicity Analysis
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Signed informed consent provided
- Age 18 years or older receiving high dose radiation overlapping previously irradiated organs at risk
- Prior radiation dosimetry available
- Stage I-IV biopsy or cytology proven solid tumor malignancy
- Recommended histologic confirmation of target lesion recurrence
- Multidisciplinary team consensus recommending re-irradiation with documented target lesion or postoperative site
- Documentation of concurrent cancer therapy drugs use and rationale
- Documented rationale if tissue confirmation of target lesion is not obtained
- Baseline imaging (CT, PET/CT, or MRI) within six weeks before enrollment
- Eligible if disease resected in previously irradiated field and at high risk of recurrence
- Measurable disease not required for postoperative treatment
- Baseline labs meeting specified limits for liver, kidney, blood counts
- ECOG performance score 0-2
- Resolution of acute toxic effects from recent cancer therapy to Grade 1 or 2
- Life expectancy of at least 6 months
- Female patients of childbearing potential must have negative pregnancy test within 7 days before treatment
- Ability to complete self-reported questionnaires
- Concurrent participation in other clinical trials involving re-irradiation allowed
You will not qualify if you...
- Receiving low dose radiation only for symptom management
- Severe or uncontrolled systemic conditions
- Life expectancy less than 6 months
- ECOG performance status of 3 or higher
- Women of childbearing potential who are pregnant or unwilling to use contraception during radiotherapy
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Froedtert Hospital
Milwaukee, Wisconsin, United States, 53226
Actively Recruiting
Research Team
M
Medical College of Wisconsin Cancer Center Clinical Trials Office
CONTACT
S
Sara Herr
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here